- Home
- MPB vs PHAR Comparison
MPB vs PHAR Comparison
Compare MPB & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPB | PHAR |
|---|---|---|
| Founded | 1868 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.9M | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MPB | PHAR |
|---|---|---|
| Price | $31.73 | $17.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $37.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 92.9K | 23.4K |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.40 | 0.00 |
| Revenue | $208,869,000.00 | ★ $362,274,000.00 |
| Revenue This Year | $26.19 | $25.19 |
| Revenue Next Year | $28.25 | $4.47 |
| P/E Ratio | ★ $13.21 | $3,043.51 |
| Revenue Growth | 20.73 | ★ 26.78 |
| 52 Week Low | $22.50 | $7.50 |
| 52 Week High | $33.24 | $18.12 |
Technical Indicators
Market Signals| Indicator | MPB | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 59.94 | 55.77 |
| Support Level | $31.64 | $16.98 |
| Resistance Level | $33.24 | $17.84 |
| Average True Range (ATR) | 0.63 | 0.67 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 56.63 | 64.97 |
Price Performance
Historical ComparisonAbout MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.